top of page

SOSTOS

Novel AI-based discoveries of biomarkers and new drug options for significantly life-prolonging outcomes

Sponsors

Our Cutting-Edge Technology
Cancer Treatment Optimization Solutions (CATOS)

Sostos Inc is a provider of cutting-edge artificial intelligence (AI)/big data technologies and health analytics services for precision medicine. CATOS products enable personalized cancer care throughout the patient journey from cancer screening, liquid biopsies, diagnosis, prognosis, treatment selection, to new drug options for patients with failed prior therapy. Our AI technology/software is proven effective in satellite system reliability assurance and precision oncology. Using our AI technology, our developed 7-gene lung cancer assay (CATOS-LU) for prognosis and prediction of therapeutic benefits has been validated in more than 1,600 patients including randomized phase III clinical trials. Using our AI/big data software, we have identified 16 therapeutic compounds as new or repositioning drugs for improving cancer patient survival outcomes. CATOS software can effectively improve cancer theranostics by efficiently analyzing multi-omics profiles of patient single cells, liquid biopsies, biopsies, and bulk tumors. Our technologies have been funded by the NSF, NASA, NIH, CDC, and CPSC. 

Our Products

Our Products

AI.png

CATOS-AI

A web portal for clinical decision making and drug repositioning

lung.png

CATOS-LU

A 7-gene lung cancer assay validated in phase III clinical trial and classified as “Novel Technology” by FDA (in review)

breast.png

CATOS-BR

A 28-gene mRNA and miRNA expression signature for breast cancer diagnosis and prognosis

Meet the Team

Meet the Team

NG.png

Founder and Chief Executive Officer

Nancy L. Guo, PhD

Dr. Guo is Fulbright U.S. Scholar for biomarker discovery. Dr. Guo obtained > $45.5M in federal funding to develop Al technology to improve healthcare. Dr. Guo was selected for the national NlH Innovator Showcase, Equalize, and NSF I-Corps programs to facilitate the commercialization of technology.

SC.png

Board Director

Stephen Carrithers, PhD

Dr. Carrithers is President, Director of R&D of AmDx PrognostX, Inc. Dr. Carrithers has led multiple diagnostics to commercialization, some of which are on the market today and one currently at the FDA as an application within the de novo 510(k) review process.

​

KC.png

Board Director

Kevin Combs

Kevin Combs is an experienced entrepreneur, investor, and founder with over 30 years of success in building and investing in companies, generating over $2 billion in revenue and returns for investors. He co-founded the Country Roads Angel Network (CRAN) to support startups in West Virginia and currently serves as CEO of PS Fertility and Molecular Biologicals, Inc. He is also a partner in Mountain Steer and is exploring opportunities in ALS diagnostics and cancer genetic testing.

DF.png

Business Advisor

Daniel C. Flynn, PhD

As vice president for research at Florida Atlantic University, Dr. Flynn promoted local entrepreneurship and economic development and expanded the university's corporate research partnerships globally. Dr. Flynn was the scientific creator of Protea Biosciences, a biotechnology company that lasted 17 years and employed 50 employees. Dr. Flynn also served on the board of BioArkive and assisted with the M&A of the company to Immuneering, Inc (12/20/21).

RJ.png

Business Advisor

Ray Johnson, DBA MBA

Ray Johnson is a serial entrepreneur with over 30 years of experience in launching, funding, and scaling small businesses in the machinery, electronics. medical device, biotech and clean-tech industrial sectors. He has served as the CEO, President, or Managing Director of six start-up and early-stage companies, which he successfully led to maturity, profitability, and exit.

​

​

QY.png

Qing Ye, PhD

Chief Technology Officer

AI / Big Data

SM.png

Seth Mizia

Data Analyst

Pharmaceutical Simulation

AC.png

Adam Cersosimo

Data Scientist I

Network Generation & Analysis

KM.png

Kathy Mangold, PhD

Medical Laboratory Advisor

Molecular Diagnosis

AD.png

Afshin Dowlati, MD

Clinical Advisor

Thoracic Oncology

TH.png

Thomas Hensing, MD

Clinical Advisor

Thoracic Oncology

DC.png

David Carbon, MD PhD

Clinical Advisor

Thoracic Oncology

Publications
publication background.jpg

Academic Publications

Recent publications

  • Wang, J., Ye, Q., Liu, L., Guo, N. L., & Hu, G. (2024). Scientific figures interpreted by ChatGPT: strengths in plot recognition and limits in color perception. NPJ precision oncology, 8(1), 84.

  • Ye, Q., Raese, R. A., Luo, D., Feng, J., Xin, W., Dong, C., ... & Guo, N. L. (2023). MicroRNA-Based Discovery of Biomarkers, Therapeutic Targets, and Repositioning Drugs for Breast Cancer. Cells, 12(14), 1917.

  • Ye, Q., Wang, J., Ducatman, B., Raese, R. A., Rogers, J. L., Wan, Y. W., ... & Guo, N. L. (2023). Expression-Based Diagnosis, Treatment Selection, and Drug Development for Breast Cancer. International Journal of Molecular Sciences, 24(13), 10561.

  • Ye, Q., Raese, R., Luo, D., Cao, S., Wan, Y. W., Qian, Y., & Guo, N. L. (2023). MicroRNA, mRNA, and Proteomics Biomarkers and Therapeutic Targets for Improving Lung Cancer Treatment Outcomes. Cancers, 15(8), 2294.

  • Ye, Q., & Guo, N. L. (2022). Inferencing Bulk Tumor and Single-Cell Multi-Omics Regulatory Networks for Discovery of Biomarkers and Therapeutic Targets. Cells, 12(1), 101.

  • Ye, Q., & Guo, N. L. (2022). Hub Genes in Non-Small Cell Lung Cancer Regulatory Networks. Biomolecules, 12(12), 1782.

  • Ye, Q., Hickey, J., Summers, K., Falatovich, B., Gencheva, M., Eubank, T. D., ... & Guo, N. L. (2022). Multi-Omics Immune Interaction Networks in Lung Cancer Tumorigenesis, Proliferation, and Survival. International Journal of Molecular Sciences, 23(23), 14978.

  • Majumder, N., Deepak, V., Hadique, S., Aesoph, D., Velayutham, M., Ye, Q., ... & Hussain, S. (2022). Redox Imbalance in COVID-19 Pathophysiology. Redox Biology, 56, 102465.

  • Ye, Q., & Guo, N. L. (2022). Single B Cell Gene Co-Expression Networks Implicated in Prognosis, Proliferation, and Therapeutic Responses in Non-Small Cell Lung Cancer Bulk Tumors. Cancers, 14(13), 3123.

  • Ye, Q., Falatovich, B., Singh, S., Ivanov, A. V., Eubank, T. D., & Guo, N. L. (2021). A Multi-Omics Network of a Seven-Gene Prognostic Signature for Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 23(1), 219.

  • Ye, Q., Singh, S., Qian, P. R., & Guo, N. L. (2021). Immune-Omics Networks of CD27, PD1, and PDL1 in Non-Small Cell Lung Cancer. Cancers, 13(17), 4296.

  • Ye, Q., Putila, J., Raese, R., Dong, C., Qian, Y., Dowlati, A., & Guo, N. L. (2021). Identification of Prognostic and Chemopredictive MicroRNAs for Non-Small-Cell Lung Cancer by Integrating SEER-Medicare Data. International Journal of Molecular Sciences, 22(14), 7658.

  • Ye, Q., Mohamed, R., Dakhlallah, D., Gencheva, M., Hu, G., Pearce, M. C., ... & Guo, N. L. (2021). Molecular Analysis of ZNF71 KRAB in Non-Small-Cell Lung Cancer. International Journal of Molecular Sciences, 22(7), 3752.

  • Guo, N. L., Bello, D., Ye, Q., Tagett, R., Chanetsa, L., Singh, D., ... & Demokritou, P. (2020). Pilot Deep RNA Sequencing of Worker Blood Samples from Singapore Printing Industry for Occupational Risk Assessment. NanoImpact, 19, 100248.

  • Snyder-Talkington, B. N., Dong, C., Singh, S., Raese, R., Qian, Y., Porter, D. W., ... & Guo, N. L. (2019). Multi-Walled Carbon Nanotube-Induced Gene Expression Biomarkers for Medical and Occupational Surveillance. International Journal of Molecular Sciences, 20(11), 2635.

  • Guo, N. L., Poh, T. Y., Pirela, S., Farcas, M. T., Chotirmall, S. H., Tham, W. K., ... & Demokritou, P. (2019). Integrated Transcriptomics, Metabolomics, and Lipidomics Profiling in Rat Lung, Blood, and Serum for Assessment of Laser Printer-Emitted Nanoparticle Inhalation Exposure-Induced Disease Risks. International Journal of Molecular Sciences, 20(24), 6348.

  • Snyder-Talkington, B. N., Dong, C., Castranova, V., Qian, Y., & Guo, N. L. (2019). Differential Gene Regulation in Human Small Airway Epithelial Cells Grown in Monoculture versus Coculture with Human Microvascular Endothelial Cells Following Multiwalled Carbon Nanotube Exposure. Toxicology Reports, 6, 482-488.

  • Guo, N. L., Dowlati, A., Raese, R. A., Dong, C., Chen, G., Beer, D. G., ... & Qian, Y. (2018). A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-Small Cell Lung Cancer. EBioMedicine, 32, 102-110.

Our AI technology for satellite system reliability assurance

  • Ma, Y., Guo, L., & Cukic, B. (2007). A Statistical Framework for the Prediction of Fault-Proneness. In Advances in Machine Learning Applications in Software Engineering (pp. 237-263). IGI Global.

  • Guo, L., Mukhopadhyay, S., & Cukic, B. (2004, June). Does Your Result Checker Really Check?. In International Conference on Dependable Systems and Networks, 2004 (pp. 399-404). IEEE.

  • Guo, L., Cukic, B., & Singh, H. (2003, October). Predicting Fault Prone Modules by the Dempster-Shafer Belief Networks. In 18th IEEE International Conference on Automated Software Engineering, 2003. Proceedings. (pp. 249-252). IEEE.

Contact Us

Investors and Customers
Please Contact Us!

Thanks for submitting!

E-verify.png
bottom of page